Novo Nordisk is adding significant risk reduction in major cardiac events (cardiac death, MI, or stroke) to the list of reasons to consider its wildly popular Wegovy weight loss drug with an announcement this week that its huge phase 3 SELECT trial successfully met its primary objective. | Novo Nordisk 2023
